SLCO1B1
Gastrointestinal & Hepatic System · Phase I & Phase II Xenobiotic Detoxification
Why can a liver transporter such as SLCO1B1 matter for medicines?
SLCO1B1 makes OATP1B1, which brings selected compounds from blood into liver cells. Differences in transport can influence drug handling, so medication-specific interpretation matters more than a general label of good or bad metabolism.
- Common Gene Name
- solute carrier organic anion transporter family member 1B1
- NCBI Gene ID
- 10599
- Chromosome
- 12
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (8 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Rotor syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2013-02 | |
| Simvastatin | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Atorvastatin | FDA pharmacogenetics | Pharmacokinetics only | Drug-specific subgroup | View source |
| Elagolix | FDA pharmacogenetics | Pharmacokinetics only | Drug-specific subgroup | View source |
| Rosuvastatin | FDA pharmacogenetics | Pharmacokinetics only | Drug-specific subgroup | View source |
| Elagolix | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Gynecology | View source |
| Rosuvastatin | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Endocrinology | View source |
| Viloxazine (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Psychiatry | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Gastrointestinal & Hepatic System